| 
		U.S. FDA warns of hidden drug ingredients in certain supplements 
		products
		 Send a link to a friend 
		
		 [April 21, 2022] 
		(Reuters) - The U.S. Food and Drug 
		Administration (FDA) on Wednesday asked people to not buy or use certain 
		dietary supplement products sold with variations of the names 'Artri' or 
		'Ortiga' as they may contain some potentially harmful ingredients not 
		mentioned on their labels. 
 The agency said its laboratory analyses revealed some of the products 
		contain dexamethasone, a corticosteroid, anti-inflammatory drug 
		diclofenac sodium and methocarbamol, which is a muscle relaxant.
 
 The products are marketed to treat arthritis, muscle pain and other 
		conditions and are sold online and in some retail stores, the agency 
		said. The FDA said it found the hidden drug ingredients in Artri Ajo 
		King, Artri King, Ortiga Mas Ajo Rey and Ortiga Mas Ajo Rey Extra Forte 
		products.
 
 The FDA in January had first issued a warning about Artri Ajo King, 
		asking consumers not to purchase the product sold for joint pain and 
		arthritis on various websites, including Amazon.com.
 
		
		 
		[to top of second column] | 
            
			 
            
			Signage is seen outside of the Food and Drug Administration (FDA) 
			headquarters in White Oak, Maryland, U.S., August 29, 2020. 
			REUTERS/Andrew Kelly 
            
			 The agency said it has received 
			reports of adverse events including of liver toxicity and death, 
			associated with the use of Artri King products since the warning. 
			The Artri King products are made by supplements maker NaturaMex.
 Dexamethasone could cause serious adverse events including 
			infections and elevated sugar levels while diclofenac sodium could 
			lead to heart attack and stroke or gastrointestinal damage, the FDA 
			warned on Wednesday. Methocarbamol may cause dizziness and low blood 
			pressure, it said.
 
 (Reporting by Amruta Khandekar; Editing by Krishna Chandra Eluri)
 
			[© 2022 Thomson Reuters. All rights 
				reserved.]  This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |